Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8504883 | 0.85 | ALDH1A1 (0.45) | ALDH1A1LMNAKDM4ETSHRACHE | |
| SCHEMBL79747 | 0.82 | HTT (0.62) | HTTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL122771 | 0.82 | HTT (0.68) | HTTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15231351 | 0.82 | MAOB (0.54) | HTTALDH1A1LMNAMEN1KMT2A | |
| Bromide SCHEMBL15391224 | 0.81 | HTT (0.61) | HTTALDH1A1LMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6162321 | 0.81 | HTT (0.66) | HTTALDH1A1LMNAMEN1KMT2A | |
| Water SCHEMBL28303092 | 0.81 | HTT (0.61) | HTTALDH1A1LMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2313460 | 0.81 | HTT (0.61) | HTTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL9320386 | 0.81 | HTT (0.66) | HTTALDH1A1LMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30519814 | 0.79 | HTT (0.59) | HTTALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332515-B2 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070123528-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | US | disclosed |
| US-7166636-B2 | Type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, or hyperglucagonemia; methyl (S)-5-{1-[(5-chloro-1H-indol-2-ylcarbonyl)amino]-2-phenylethyl}oxazole-4-carboxylate; amidation by reacting the 2-carboxyindole and a 1,2-diphenylethylamine | ASTRAZENECA AB (SE) | 2007-01-23 | — | — | US | disclosed |
| EP-1483271-B1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-7138415-B2 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-11-21 | — | — | US | disclosed |
| US-7122567-B2 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050130963-A1 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRA ZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1483240-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1483271-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074531-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074484-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | PYGL, PYGM, PYGB | HTT 1246/4885ALDH1A1 3014/4885LMNA 836/4885 |
| US-20050130963-A1 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | GYS1, PYGL, GYS2 | HTT 1189/4885ALDH1A1 3962/4885LMNA 1042/4885 |
| US-20070123528-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | PYGL, PYGM, PYGB | HTT 1265/4885ALDH1A1 1717/4885LMNA 227/4885 |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | PYGL, GYS1, CBR3 | HTT 1192/4885ALDH1A1 3143/4885LMNA 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.